

Boston Scientific Announces Schedule of Events at TCT Conference

PRNewswire
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., Sept. 16 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from September 21 to 25 in San Francisco.

"We look forward to the presentation of additional clinical data reinforcing the safety, efficacy and deliverability of our two distinct drug-eluting stent (DES) platforms -- TAXUS® and PROMUS®," said Donald S. Baim, M.D., Executive Vice President, Chief Medical and Scientific Officer at Boston Scientific. "We also anticipate positive three-year data from the TAXUS ATLAS trials, assessing the performance of our second-generation TAXUS® Liberte Atom™ and Long Stents in patients with small vessels and long lesions. Boston Scientific is the only company to offer FDA-approved 2.25 mm diameter and 38 mm length drug-eluting stents."

Schedule of Events (All times are PT; all events are held at the Moscone Center.)

Monday, September 21

- **PROMUS and TAXUS Express® Stents.** Gregg W. Stone, M.D., will present three-year data from the SPIRIT III Clinical Trial during a Drug-Eluting Stent Summit at 5:43 p.m. in Room 104. SPIRIT III is a randomized, non-inferiority trial of 1,002 patients treated with the XIENCE V® (PROMUS) Stent or the TAXUS Express Stent. The Company plans to issue a press release at this time.

Tuesday, September 22

- **TAXUS ATLAS Small Vessel, Long Lesion and Direct Stenting studies.** Mark A. Turco, M.D., Co-Principal Investigator of the TAXUS ATLAS trials, will present three-year data from the TAXUS ATLAS Small Vessel and TAXUS ATLAS Long Lesion trials in a poster session beginning at 8:00 a.m. in Hall D. Results will assess the long-term benefit of the TAXUS Liberte Atom 2.25 mm stent in small vessels and the TAXUS Liberte Long 38 mm stent in long lesions. The same poster session will feature three-year data from the TAXUS ATLAS Direct Stent trial presented by John A. Ormiston, M.D. TAXUS ATLAS is a global, multi-center, single-arm study designed to demonstrate that the TAXUS Liberte Stent is non-inferior in safety and efficacy to the TAXUS Express Stent. The Company plans to issue a press release at this time.
- **SYNTAX Study data.** Several oral abstracts on multivessel disease revascularization featuring analysis from the landmark SYNTAX trial will be presented in Room 131 from 10:00 a.m. to 12:00 p.m. Ted Feldman, M.D., will present an analysis of outcomes after repeat revascularization from the SYNTAX trial. Patrick W. Serruys, M.D., will present a new assessment of the reproducibility of the SYNTAX Score, a novel angiographic tool used to measure the complexity of coronary artery disease. Michael J. Mack, M.D., will present an analysis of stroke occurring in SYNTAX patients. SYNTAX is the first randomized, controlled clinical trial comparing percutaneous coronary intervention using drug-eluting stents to coronary artery bypass graft surgery in patients with left main and/or three-vessel disease.

Wednesday, September 23

- **PROMUS and TAXUS Express Stents.** Dr. Stone will present one-year results from the SPIRIT IV Clinical Trial at 11:00 a.m., during a Late-Breaking Trials session in the Esplanade Ballroom. SPIRIT IV is a prospective, single-blinded, multicenter clinical trial with 3,690 patients randomized 2:1 to the XIENCE V (PROMUS) Stent or the TAXUS Express Stent. The primary end point is the rate of ischemia-driven target lesion failure at one year. The Company plans to issue a press release at this time.

Friday, September 25

- **HORIZONS-AMI Two-Year Data.** Dr. Stone will present two-year data from the HORIZONS-AMI clinical trial at 11:30 a.m., during a Late-Breaking Trials session in the Esplanade Ballroom. HORIZONS-AMI is a randomized, controlled clinical trial designed to compare TAXUS stents to bare-metal stents in 3,400 AMI (acute myocardial infarction) patients. The Company plans to issue a press release at this time.

Boston Scientific will present its latest cardiovascular products at booth #716 in the Exhibition Hall, including the TAXUS Liberte Atom and TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent Systems, and the iLab System 2.0 Software upgrade. The Company will also feature emerging DES innovations, including the platinum chromium Element Stent platform and new bioabsorbable coating technologies.

TAXUS, Express, Express2, Liberte, Atom, PROMUS and Element are trademarks of Boston Scientific Corporation or its affiliates. XIENCE V is a trademark of Abbott Laboratories group of companies. The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. The SPIRIT Clinical Program is sponsored by Abbott. The TAXUS Express Stent was the control in the SPIRIT III and SPIRIT IV clinical trials.

In the United States, the TAXUS Element Stent and PROMUS Element Stent are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

The safety and effectiveness of the TAXUS Stents has not been established in direct stenting procedures, in patients with an acute myocardial infarction, or in patients with left main or three-vessel disease.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, new product launches, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press

release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan
508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://news.bostonscientific.com/news-releases?item=59180>